One, They are running a business. That is the plan. I'm not sure what people expected from the new management team. The US market has been impacted by an inexperienced, possibly politically motivated judge. Markets outside of the US are slowly opening up. That is where we are. Amarin is no longer a biotech company. They are a pharmaceutical company. They have a solid cash balance, no debt, and a valuable product. The company is doing what they can to protect US revenue while they grow revenue in unimpaired markets. That was the plan of the prior management. It's the plan of new management. We know the plan. As investors we need to decide if we think "the plan" will succeed.
Sleven,
Market Data 
Markets 
AI
